Sleep Disorders

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

Your daily dose of the clinical news you may have missed.

Review authors emphasized the need for a more comprehensive approach to dementia management.

Your daily dose of the clinical news you may have missed.

Findings from a recent review highlight the impact of common analgesic medications on sleep patterns in people with chronic pain.

ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.

Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Women aged 40 to 65 years who had persistent insomnia and poor sleep duration were at a 75% greater risk for incident CVD over 2 decades of follow up.